Avidity Biosciences Inc
RNAM
Clasificación en acciones
#2082
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Precio por acción
$71.34
Última sincronización: 2026-03-03
Capitalización bursátil
$9.84B
Cambio (1 día)
0.00%
Cambio (1 año)
-
País
US
Comercio Avidity Biosciences Inc (RNAM)
Categoría
Healthcare
Historial de rendimiento por dividendo de Avidity Biosciences Inc (RNAM)
Rendimiento por dividendo (TTM) de Avidity Biosciences Inc (símbolo bursátil: RNAM) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Avidity Biosciences Inc (RNAM) desde 2018 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
| Año | Rendimiento por dividendo | Cambiar |
|---|---|---|
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Rendimientos por dividendo (TTM) de empresas similares o competidoras
| Empresa | Rendimiento por dividendo | País |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.07% |
AU
|
|
| 0.00% |
NL
|
|
| 0.72% |
BE
|
